The Russian retail market for nebulizers (including the online and FMCG segments) totalled 3.59 billion RUB in the first ten months of 2025 (in retail prices, including VAT). Compared with the same period of the previous year, the sales value of these devices declined by 10.9%. This was accompanied by a reduction in unit demand, which decreased by 6.1% year-on-year: from January to October of the current year, Russian consumers purchased almost 1.64 million nebulizers. The relatively weak demand this year is evidently directly related to morbidity trends; a similar pattern is observed for other medical devices. In particular, in the first ten months of 2025, consumption of medical thermometers also declined. Moreover, the usual peak in sales of inhalation devices typically falls in December, whereas in 2024 the highest demand in this category was already recorded in October. Over the whole of 2024, a total of 2.21 million devices were sold for 4.98 billion RUB. Compared to 2023, the value dynamics in RUB amounted to +3.9%, while unit consumption increased by 15.5%.

An important trend in recent years has been the considerable pressure exerted by online platforms on traditional sales channels. In the current year, the market for portable inhalation devices has developed exclusively due to the expansion of the e-commerce segment. According to the “Audit of Retail Sales of Medical Devices in Russia (total sell out)” database of the analytics company RNC Pharma, in January–October 2025 more than 51.5% of total nebulizer unit sales in the retail market fell on the online channel, primarily on marketplaces. Moreover, despite the overall decline in demand, the unit volume of nebulizer sales via the internet increased by 3%, while expenditure in this channel decreased by 3%. The offline channel, compared with the first ten months of the previous year, shows a pronounced decline both in unit terms (–14%) and in value terms (–15%). The share of pharmacies and the FMCG channel is shrinking rapidly, and this trend is particularly evident in the pharmacy segment: if in 2022 this channel accounted for 69% of nebulizer sales, then in the current year pharmacies generated only 46.3%. The share of the FMCG segment fell from 6% (in 2022) to 2.2% (in January–October 2025).

By the end of the ten-month period, more than 60 brands of nebulizers were present on the retail market. The category leader remains the Japanese brand Omron with a value share of 27.8%; in second place is the Swiss brand B.Well (22%), and closing the top three is the Japanese brand A&D (16.3%). Notably, all three leading brands recorded a decline in sales during the reporting period. Within the top ten brands, only three showed positive dynamics. These include the Chinese brand MVMED, whose sales volume increased by 53% year-on-year. The Swiss device Microlife also deserves mention, with sales growth of +11%, as well as the Chinese brand Xiaomi (+17%). However, the main reason for the decline in demand for branded devices has been the extremely strong growth of unbranded “no-name” products, which compete aggressively on price with the leading brands.

Fig. Structure of the Russian retail nebulizer market by sales channel in volume terms, %, units